(MedPage Today) — The FDA will decide whether to approve a once-daily, 25 mg oral formulation of semaglutide (Wegovy) by the end of 2025. If approved, it would be the first GLP-1 pill indicated for obesity, said maker Novo Nordisk. The rate of…
We recently published a list of 21 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other stocks on Jim Cramer’s radar. On Friday, Mad Money host Jim Cramer discussed this week’s main market drivers and placed emphasis on earnings reports … Read more
In 2023, the American Society of Anesthesiologists recommended discontinuing glucagon-like peptide-1 (GLP-1) receptor agonists before surgery over concerns about increased risk of aspiration pneumonia. But a study recently found no significant difference in postoperative aspiration pneumonia incidence between GLP-1 users and nonusers.
Glucagon-like peptide (GLP-1) receptor agonists like semaglutide and liraglutide are already game-changers for obesity and type 2 diabetes. Could addiction be next?
TOPPING the scales at 16 stone, Joann Burland knew something had to change. At 5ft 2in and a size 20, the 49-year-old from Basildon, Essex, was tired of hiding in baggy clothes and exhausted from years of failed diets. John McLellanJoann now feels better both mentally and physically[/caption] SuppliedJoann, pictured with son Luke and husband … Read more
Annals of Internal Medicine, Ahead of Print.
<div><p paraid=”1052830088″ paraeid=”{1c084551-346b-4cb6-8208-64c606d219f8}{9}”><b>By Bio-IT World Staff </b></p></div><div><p paraid=”535832799″ paraeid=”{1c084551-346b-4cb6-8208-64c606d219f8}{15}”><b>May 6, 2025</b> | Last week Illumina and Ovation.io announced the development of the largest commercially-available clinical multiomic dataset from 25,000 patients treated with glucagon-like peptide-1 (GLP-1) receptor agonist therapies. The dataset will be made available to the pharma community to advance drug discovery and development. This collaboration … Read more
Wegovy resolved liver inflammation in nearly two-thirds of participants in a major clinical trial, twice the rate seen with placebo. Steve Christo-Corbis/Getty Images Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 drug resolved liver inflammation in nearly two-thirds of participants, twice the rate … Read more
Interest in weight-loss products continues to surge as calls come for a faster rollout of treatments on the NHS. Research by Harley Street Skin Clinic found semaglutide – sold under the brand names Wegovy for weight loss and Ozempic for diabetes – is the most searched weight-loss medication, with over 16 million Google searches last … Read more
